Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

20.40
-1.6200-7.36%
Volume:1.26M
Turnover:26.19M
Market Cap:2.15B
PE:-15.50
High:21.82
Open:21.81
Low:20.28
Close:22.02
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:0.36
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.41
PE(LYR):-2.86

Loading ...

Sarepta Therapeutics (SRPT) Stock Could Be 19% Undervalued As Elevidys Outlook Steadies

Simply Wall St.
·
Jun 21

Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says

MT Newswires Live
·
Jun 18

Is Sarepta Therapeutics (SRPT) Quietly Rewriting Its Risk Profile With New Equity Plans And Q1 Profitability?

Simply Wall St.
·
Jun 08

A Look At Sarepta Therapeutics (SRPT) Valuation After New Shelf Registration For Potential Share Offering

Simply Wall St.
·
Jun 06

Sarepta Therapeutics shareholders approve 2026 equity incentive plan at annual meeting

Reuters
·
Jun 05

SRPT Expands Into Huntington’s Disease With New First-in-Human Trial

TIPRANKS
·
Jun 05

Acting US FDA chief meets with rare disease groups to mend fences

Reuters
·
Jun 04

Sarepta Therapeutics to present at Goldman Sachs Global Healthcare Conference

Reuters
·
Jun 02

A Look At Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness And ELEVIDYS Safety Concerns

Simply Wall St.
·
May 27

J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)

TIPRANKS
·
May 19

Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says

MT Newswires Live
·
May 15

Sarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target Unchanged

TIPRANKS
·
May 15

Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026

TIPRANKS
·
May 11

Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says

MT Newswires Live
·
May 09

Sarepta Therapeutics Shares Down 3.3% After Lower Q1 Sales for Gene Therapy

THOMSON REUTERS
·
May 07

H.C. Wainwright Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)

TIPRANKS
·
May 07

Sarepta Therapeutics (SRPT) Gets a Hold from RBC Capital

TIPRANKS
·
May 07

BUZZ-Sarepta falls on lower quarterly sales for gene therapy

Reuters
·
May 07

Sarepta Therapeutics Shares Slump 13.2% Premarket to $20 After Q1 Results

THOMSON REUTERS
·
May 07

Stock Track | Sarepta Therapeutics Plunges 6.86% Pre-Market on Disappointing Q1 Revenue and Sharp ELEVIDYS Sales Decline

Stock Track
·
May 07